Open Government Portal

Found 10 records similar to Introduction to the Canada's Access to Medicines Regime

Federal

Canada's Access to Medicines Regime provides a way for the world's developing and least-developed countries to import high-quality drugs and medical devices at a lower cost to treat the diseases that bring suffering to their citizens.

Last Updated: Sep. 17, 2020
Date Published: Apr. 25, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, developing and least-developed countries, import high-quality drugs and medical devices, a lower cost drug and medical devices.
Federal

Countries with insufficient or no manufacturing capacity in the pharmaceutical sector can benefit from participating in Canada's Access to Medicines Regime. Under the Regime, eligible countries can import less expensive, generic versions of patented products manufactured in Canada.

Last Updated: Sep. 17, 2020
Date Published: Mar. 29, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Country access, Canada's Access to Medicines Regime, insufficient or no manufacturing capacity in the pharmaceutical sector, import a lower cost drug and medical devices.
Federal

It presents the list Least-Developed Countries Eligible to Import Under the Regime.

Last Updated: Sep. 17, 2020
Date Published: Mar. 17, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, Least-developed countries, countries eligible to import under the Regime.
Federal

A pharmaceutical company that holds a compulsory licence under Canada's Access to Medicines Regime is required to pay royalties to the patent holder. The company must make payments within a prescribed amount of time and in accordance with a prescribed formula.

Last Updated: Sep. 17, 2020
Date Published: Apr. 28, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, company that holds a compulsory licence, patent holder, Royalty payments.
Federal

In August 2003, negotiations among World Trade Organization (WTO) members resulted in a landmark decision to waive two licensing provisions of the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) that appeared to prevent the export of generic drugs and medical devices to developing countries faced with public health problems.

Last Updated: Sep. 17, 2020
Date Published: Mar. 28, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, World Trade Organization, waive licensing provisions, WTO Agreement, Intellectual Property Rights, developing and least-developed countries, import high-quality drugs and medical devices
Federal

The legislation establishing Canada's Access to Medicines Regime contains a "Good Faith Clause" that provides patent holders with the right to challenge a compulsory licence in the Federal Court of Canada. A challenge can be mounted if the patent holder believes the licence is being used for predominantly commercial rather than humanitarian purposes.

Last Updated: Sep. 17, 2020
Date Published: Mar. 29, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, Good faith clause, patent holders, right to challenge, compulsory licence.
Federal

Governments can override patent rights when necessary. In such instances, the government authorizes a third party to use the patented invention without the patent holder's permission. This authorization comes in the form of a compulsory licence.

Last Updated: Sep. 17, 2020
Date Published: Mar. 29, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, compulsory licences, override patent rights, authorizes a third party, patented invention, patent holder's permission.
Federal

It presents the Patent Act Schedules #1, #2, #3 and #4.

Last Updated: Sep. 17, 2020
Date Published: Mar. 17, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, Patent Act Schedules.
Federal

The patent holder may seek an order from the Federal Court of Canada to terminate a compulsory licence, if the patent holder can establish that any information in the application by the licence holder is inaccurate or that the licence holder has failed

Last Updated: Sep. 17, 2020
Date Published: Mar. 29, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, termination of authorization, terminate a compulsory licence, patent holder, Federal Court of Canada.
Federal

The company must submit the application package to the Commissioner of Patents at the Canadian Intellectual Property Office (CIPO).

Last Updated: Sep. 17, 2020
Date Published: Apr. 28, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, submit the application package, the Commissioner of Patents at the Canadian Intellectual Property Office.
Date modified: